The dynamics of the minimal residual disease market are anticipated to change as the future of guided therapies, improvements in the next-generation sequencing detection methods, and the increased use of MRD testing can increase the market share in the near future
LAS VEGAS, March 1, 2023 /PRNewswire/ -- DelveInsight's Minimal Residual Disease Market Insights report includes a comprehensive understanding of current treatment practices, minimal residual disease emerging products, market share of individual products, and current and forecasted market size from 2019 to 2032, segmented into 7MM [the United States, the EU-4 (Italy, Spain, France, and Germany), the United Kingdom, and Japan].
Key Takeaways from the Minimal Residual Disease Market Report
- As per DelveInsight analysis, the minimal residual disease market size in the 7MM was approximately 700 million in 2021.
- According to the assessment done by DelveInsight, the total minimal residual disease testing cases in the 7MM were found to be USD1.2 million in 2021.
- Leading minimal residual disease companies, such as Adaptive Biotechnologies, Foresight Diagnostics, Ceregentis B.V., ICON Plc, 3B BlackBio-Biotech, Natera, EntroGen, Quest Diagnostics, Hangzhou ImmuQuad Biotechnologies, Mission Bio, Biocartis, and others are involved in the development of diagnostic methods for the diagnosis of MRD in patients with cancer. The introduction of these methods might get an advantage in market space due to course.
- The promising minimal residual disease products include ClonoSEQ, PhasED-Seq, Targeted Locus Amplification (TLA) technology, MRDx BCR-ABL Test, TRUPCR® PML-RARA, Signatera, Leukemia Fusion Gene One-Step Detection Kits, CBFB/MYH11 inv(16), Seq-MRD, LymphoTrack, Idylla Technology, and others.
Discover which product will grab the major minimal residual disease market share @ Minimal Residual Disease Market Report
Minimal Residual Disease Overview
Minimal residual disease (MRD) is a small number of cancer cells that remain in the body after treatment. These cells have the potential to resurface and cause a relapse. In leukemia, for example, physicians look for a response after chemotherapy treatment by looking for cancer cells in a bone marrow biopsy under a microscope. An MRD positive test result indicates that the disease remained after treatment. An MRD negative result indicates that no disease was detected after treatment. Patients with MRD may have so few remaining cancer cells that traditional tests, such as viewing cells under a microscope, cannot detect them.
Measurable or minimal residual disease (MRD) testing is used to determine whether or not cancer treatment is effective and to guide future treatment plans. MRD testing is currently being studied in other cancers besides blood cancers (leukemia, lymphoma, and myeloma). Because the results can be used to tailor your treatment plan, it is a type of personalized medicine. MRD tests employ extremely sensitive techniques such as multiparametric flow cytometry, polymerase chain reaction (PCR), and next-generation sequencing (NGS).
Minimal Residual Disease Epidemiology Segmentation
DelveInsight estimates that in the year 2021, the total minimal residual disease testing cases in the 7MM were found to be 1.2 million. The most number of MRD testing cases were found in the US, followed by Germany.
In Germany, the total number of MRD testing during new therapy and maintenance was found to be approximately 38 thousand and 97 thousand, respectively, in the year 2021.
The minimal residual disease market report proffers epidemiological analysis for the study period 2019-2032 in the 7MM segmented into:
- Total MRD testing
- Total MRD cases by cancer type
- Total MRD testing from different blood cancers
- Total MRD testing for HSCT-related transplant
- Total MRD testing during new therapy and maintenance therapy
- Total number of MRD Testing by age
Download the report to understand which factors are driving minimal residual disease epidemiology trends @ Minimal Residual Disease Epidemiological Insights
Minimal Residual Disease Testing Market Insights
MRD is detected using highly sensitive methods such as multiparameter flow cytometry (MFC), which detects antigen expression on neoplastic cells compared to normal cells, polymerase chain reaction (PCR), which increases trace amounts of DNA so that a specific segment of DNA can be studied, and next-generation sequencing (NGS). Currently, patients are treated until they achieve complete remission (CR). This could be accomplished through surgical resection, radiation therapy, chemotherapy, or a combination of these treatments. Patients are usually monitored until they relapse. Instead, MRD could be sampled iteratively, tested for therapeutic susceptibility, and treated with the agents identified as most effective by that test. When a patient's MRD falls below the minimum detectable threshold (dashed line), treatment can be stopped, continued indefinitely, or continued with curative intent for a set period.
The ClonoSEQ is the first FDA-approved assay for detecting measurable residual disease. It detects MRD in bone marrow from patients with multiple myeloma (MM) and B-cell lymphoblastic leukemia (ALL), as well as blood or bone marrow from patients with chronic lymphocytic leukemia (CLL). The clonoSEQ is an MRD assessment tool that uses next-generation sequencing (NGS) technology and is distinguished from other NGS assays by groundbreaking chemistry advances and proprietary bioinformatics.
To know more about minimal residual disease testing guidelines, visit @ Minimal Residual Disease Testing Methods
Minimal Residual Disease Products and Key Companies
- ClonoSEQ: Adaptive Biotechnologies
- PhasED-Seq: Foresight Diagnostics
- Targeted Locus Amplification (TLA) technology: Cergentis B.V.
- MRDx BCR-ABL Test: ICON plc
- TRUPCR® PML-RARA: 3B BlacBio Biotech India
- Signatera: Natera
- Leukemia Fusion Gene One-Step Detection Kits: EntroGen
- CBFB/MYH11 inv(16): Quest Diagnostics
- Seq-MRD: ImmuQuad
- LymphoTrack: Invivoscribe Inc.
- Idylla Technology: Biocartis
Learn more about the FDA-approved products for minimal residual disease @ New Methods for Minimal Residual Disease Testing
Minimal Residual Disease Market Dynamics
The dynamics of the minimal residual disease market is expected to change in the coming years. Several organizations and companies, including the European Scientific Foundation for Laboratory Hemato Oncology (ESLHO), the Leukemia and Lymphoma Society (LLS), and European LeukemiaNet (ELN), are raising awareness about the disease, which may result in a larger patient pool. Moreover, recent advances in high-throughput molecular genetics technologies, such as next-generation sequencing (NGS), may now provide a novel approach to detecting MRD.
In addition, increased use of MRD testing can open up new avenues by identifying patients who may benefit from consolidative HDT-ASCT and prolonged therapy. Furthermore, the development of more precise diagnostic methods with high sensitivity allows for the detection of even the smallest number of MRD cells.
However, MRD causes cancer relapse because antibodies may disappear with appropriate treatment but reappear with tumor relapse. A lack of proper diagnostic and treatment guidelines can hamper patients' conditions. Furthermore, the diagnostic scenario in the United States differs from that in Europe and Japan. There are only a few approved testing methods for assessing MRD in the United States. The MRD market is characterized by a lack of disease understanding, limited epidemiological studies, and assessment options. There is a need to develop effective patient-specific assessment options, including age. However, there is a significant unmet need to establish MRD biology for a better understanding of the disease and a significant need for expertise to carry out MRD assays.
Report Metrics | Details |
Study Period | 2019-2032 |
Coverage | 7MM [the United States, the EU-4 (Italy, Spain, France, and Germany), the United Kingdom, and Japan]. |
Base Year | 2019 |
Minimal Residual Disease Market CAGR | 14 % |
Minimal Residual Disease Market Size in 2021 | USD 1.2 Million |
Key Minimal Residual Disease Companies | Adaptive Biotechnologies, Foresight diagnostics, Ceregentis B.V., ICON Plc, 3B BlackBio-Biotech, Natera, Entrogen, Quest diagnostics, Hangzhou ImmuQuad Biotechnologies, Mission Bio, Biocartis, and others |
Key Minimal Residual DiseaseProducts | ClonoSEQ, PhasED-Seq, Targeted Locus Amplification (TLA) technology, MRDx BCR-ABL Test, TRUPCR® PML-RARA, Signatera, Leukemia Fusion Gene One-Step Detection Kits, CBFB/MYH11 inv(16), Seq-MRD, LymphoTrack, Idylla Technology, and others |
Scope of the Minimal Residual Disease Market Report
- Therapeutic Assessment: Minimal Residual Disease current marketed and emerging therapies
- Minimal Residual Disease Market Dynamics: Minimal Residual Disease market drivers and barriers
- Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
- Unmet Needs, KOL's views, Analyst's views, Minimal Residual Disease Market Access and Reimbursement
Discover more about minimal residual disease testing products in development @ Minimal Residual Disease Testing Clinical Trials
Table of Contents
1. | Minimal Residual Disease Market Key Insights |
2. | Minimal Residual Disease Market Report Introduction |
3. | Minimal Residual Disease Market Overview at a Glance |
4. | Minimal Residual Disease Market Executive Summary |
5. | Disease Background and Overview |
6. | Minimal Residual Disease Treatment and Management |
7. | Minimal Residual Disease Epidemiology and Patient Population |
8. | Patient Journey |
9. | Minimal Residual Disease Marketed Drugs |
10. | Minimal Residual Disease Emerging Drugs |
11. | Seven Major Minimal Residual Disease Market Analysis |
12. | Minimal Residual Disease Market Outlook |
13. | Potential of Current and Emerging Therapies |
14. | KOL Views |
15. | Minimal Residual Disease Market Drivers |
16. | Minimal Residual Disease Market Barriers |
17. | Unmet Needs |
18. | SWOT Analysis |
19. | Appendix |
20. | DelveInsight Capabilities |
21. | Disclaimer |
22. | About DelveInsight |
Related Reports
Hematological Cancer Therapeutics Market
Hematological Cancer Therapeutics Market Insight, Competitive Landscape, and Market Forecast - 2027 report delivers an in-depth understanding of market trends, market drivers, market barriers, and key hematological cancer therapeutics companies, including Pfizer Inc., F. Hoffmann-LA Roche Ltd, Sanofi SA, Bristol-Myers Squibb Company, AbbVie Inc, among others.
Refractory Multiple Myeloma Market
Refractory Multiple Myeloma Market Insight, Epidemiology, and Market Forecast - 2032 report delivers an in-depth understanding of the market trends, market drivers, market barriers, and key refractory multiple myeloma companies, including Takeda Oncology, ORIC Pharmaceuticals, Ionis Pharmaceuticals, Cellectis S.A., YZY Biopharma, among others.
Relapsing Refractory Multiple Myeloma Market
Relapsing Refractory Multiple Myeloma Market Insight, Epidemiology, and Market Forecast - 2032 report delivers an in-depth understanding of the market trends, market drivers, market barriers, and key relapsing refractory multiple myeloma companies, including AbbVie, Amgen, Takeda Oncology, among others.
Multiple Myeloma Market
Multiple Myeloma Market Insight, Epidemiology, and Market Forecast - 2032 report delivers an in-depth understanding of the market trends, market drivers, market barriers, and key multiple myeloma companies, including Novartis, Incyte Corporation, Arcellx, Pfizer, among others.
Acute Myeloid Leukemia Market
Acute Myeloid Leukemia Market Insight, Epidemiology, and Market Forecast - 2032 report delivers an in-depth understanding of the market trends, market drivers, market barriers, and key acute myeloid leukemia companies, including Takeda Oncology, Immunity Bio, Teva Pharmaceuticals, among others.
Acute Lymphocytic Leukemia Pipeline
Acute Lymphocytic Leukemia Pipeline Insight - 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key acute lymphocytic leukemia companies, including AbbVie, Novartis, Jazz Pharmaceutical, among others.
Other Trending Reports
Tay-sachs Disease Or Gm2 Gangliosidosis Market | Onycholysis Market | Diagnostic Imaging Equipment Market | Chemotherapy-induced Peripheral Neuropathy Market | Global Electrophysiology Devices Market | Anaphylaxis Market | Atherectomy Devices Market | Helicobacter Pylori Infections Market | Ophthalmic Imaging Equipment Market | Androgenetic Alopecia Market | Allergic Rhinitis Market | Chronic Inflammatory Demyelinating Polyneuropathy Market | Chronic Inflammtory Demyelinating Polyneuropathy Market | Colorectal Cancer Crc Market | Opioid Induced Constipation Market | Vertigo Market | Bone Anchored Hearing Systems Market | Wound Closure Devices Market | Hip Replacement Devices Market | Hemodynamic Monitoring Systems Market | Egfr Non-small Cell Lung Cancer Market | Helicobacter Pylori Infection Market | Hyperkalemia Market | Polycythemia Market Neurostimulation Devices Market | Carpal Tunnel Syndrome Market | Ventilator Market | Cerebral Aneurysm Market | Alpha Antitrypsin Market | Binge Eating Disorder Market | Bunion Market | Concussions Market Size | Exocrine Pancreatic Insufficiency Market | Healthcare Due Diligence Services | Minimal Residual Disease Market | Hypertrophic Scar Market | Lung Fibrosis Market | Anterior Uveitis Market | 22q11.2 deletion syndrome Market | X-Linked Retinitis Pigmentosa (XLRP) Market | Acute Radiation Syndrome Market | Alpha-1 Protease Inhibitor Deficiency Market | Androgenetic Alopecia Market | Hyperlipidemia Market | Cardiotoxicity Market | Hypertrophic Cardiomyopathy Market | Fatty Acid Oxidation Disorders (FAODs) Market | Androgen Insensitivity Syndrome Market | Emphysema Market | Canaloplasty Market | Dravet Syndrome Market | Celiac Disease Market | Chlamydia Infections Market | Syphilis Market | Renal Tubular Acidosis Market | Palmoplantar Pustulosis (PPP) Market | Aplastic Anemia Market | Bacterial Pneumonia Market | B cell Chronic Lymphocytic Leukemia Market | B cell Lymphomas Market | Behcets Disease Market Neoantigen-based Personalized Cancer therapeutic Vaccines Competitive Landscape and Market Forecast-by 2035 | Glioblastoma Market
Related Healthcare Blogs
Multiple Myeloma Treatment Market
Upcoming Oncology Drugs
Oncology Market Outlook
Future of Oncology Market
Related Cases Studies
Competitive Intelligence
Market Assessment
Product Assessment
Epidemiology Assessment
Related Healthcare Services
Healthcare Consulting
Healthcare Competitive Intelligence Services
Healthcare Asset Prioritization Services
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
Connect with us on LinkedIn|Facebook|Twitter
Additionally, get in touch with our business executive to explore @ Healthcare Due Diligence Services
Contact Us
Shruti Thakur
info@delveinsight.com
+1(919)321-6187
www.delveinsight.com
Logo: https://mma.prnewswire.com/media/1082265/DelveInsight_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/minimal-residual-disease-market-to-exhibit-growth-at-a-massive-cagr-of-18-during-the-study-period-20192032-assesses-delveinsight-301759173.html
